Lucid Diagnostics Inc(LUCD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 7:46 PM ET (Korea 11/4 09:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.47 | Insider Own | 21.2% | Shs Outstand | 190.8M | Perf Week | -4.82% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 31.48% | Insider Trans | 0.57% | Shs Float | 160.2M | Perf Month | -29.72% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.06 | Inst Own | 30.23% | Short Float | 8.51% | Perf Quarter | -58.3% |
| Income | -0.07B | P/S | 15.55 | EPS this Y | 37.21% | Inst Trans | 17.28% | Short Ratio | 2.81 | Perf Half Y | -61.74% |
| Sales | 0.01B | P/B | 7.28 | EPS next 5Y | 28.07% | ROA | -134.66% | Short Interest | 13.63M | Perf YTD | -61.74% |
| Book/sh | 0.06 | P/C | 2.54 | EPS past 3/5Y | 23.61% -25.34% | ROE | -556.27% | 52W High | -74.41% ($1.63) | Perf Year | -65.54% |
| Cash/sh | 0.16 | P/FCF | - | Sales past 3/5Y | 131.97% - | ROIC | -457.21% | 52W Low | 37.62% ($0.30) | Perf 3Y | -67.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.16% | Gross Margin | -37.78% | Volatility(W/M) | 14.84% 15.58% | Perf 5Y | -95.63% |
| Dividend TTM | - | EV/Sales | 13.99 | Sales Y/Y TTM | 24.89% | Oper. Margin | -930.85% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | -0.88% | Profit Margin | -1193.87% | RSI (14) | 37.5 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.33 | Sales Q/Q | 26.74% | SMA20 | -11.92% ($0.48) | Beta | 1.16 | Target Price | $4 |
| Payout | - | Debt/Eq | 2.28 | Earnings | 2026/11/12 | SMA50 | -39.75% ($0.7) | Rel Volume | 0.33 | Prev Close | $0.41 |
| Employees | 82 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | -5.82% 3.28% | SMA200 | -58.94% ($1.02) | Avg Volume(3M) | 4.85M | Price | $0.42 |
| IPO | 2021/10/14 | Option/Short | No/Yes | Trades | 2768 | Volume | 1,613,405 | Change | 2.63% |
🔬 This is a US medical diagnostics company that develops and commercializes EsoGuard, a molecular diagnostic test for the early detection of esophageal cancer. When paired with EsoCheck, a non-invasive esophageal cell collection device, the focus is on the early screening of Barrett's esophagus, a condition that can progress to esophageal adenocarcinoma.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded less than usual. That is 33% of its average volume.
Next earnings report: November 12
8 days to go.
LUCD has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,555. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.6%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 30.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #86 of 140 in the industry
Based on market cap of $85M.
NYXH#85 Nyxoah SA $89M PER - LUCD#86 Lucid Diagnostics Inc $85M PER - 
OM#87 Outset Medical Inc $78M PER - 
SERA#88 Sera Prognostics Inc $77M PER - 
HYPR#89 Hyperfine Inc $73M PER - 
FAQ
What kind of company is LUCD?
LUCD belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of LUCD?
The market cap of LUCD is approximately $85M, ranking 4,551 within its sector.
What is the 52-week high and low for LUCD?
LUCD has recorded a 52-week high of $1.63 and a low of $0.30.
